METTL3-stabilized lncRNA SNHG7 accelerates glycolysis in prostate cancer via SRSF1/c-Myc axis

Liu, Jun; Yuan, Jun-Fang; Wang, Yu‐Zhong

doi:10.1016/j.yexcr.2022.113149

Cited by 40 publications

(31 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The m6A regulators regulated the m6A methylation in MYC, affecting the stability and translation efficiency of MYC, and then regulated the expression of MYC, which was an important mechanism for the occurrence and development of cancers ( Wu et al, 2021 ; Zheng et al, 2022 ). The m6A regulators of METTL3/5, FTO, IGF2BP1/2/3, YTHDF2 ( Einstein et al, 2021 ; Iaiza et al, 2021 ; Yang et al, 2021 ; Chen et al, 2022 ; Du et al, 2022 ; Hu et al, 2022 ; Huang et al, 2022 ; Liu et al, 2022 ; Luo and Lin, 2022 ), and so on had been proven to modulate the mechanism. In our study, compared with the healthy control, MYC mRNA levels were lower in both NAFL and NASH, while no differences were found between NAFL and NASH.…”

Section: Discussionmentioning

confidence: 99%

New roles of N6-methyladenosine methylation system regulating the occurrence of non-alcoholic fatty liver disease with N6-methyladenosine-modified MYC

Cheng

Zhang

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) has become a major chronic disease in contemporary society, affected by N6-methyladenosine (m6A) RNA methylation, one of the most common RNA modifications. Compared with healthy control, m6A RNA methyltransferase 3 (METTL3) and METTL14 increased, while Wilms tumor 1-associated protein (WTAP) and RNA-binding motif protein 15 (RBM15) decreased significantly in NAFLD, and the m6A demethylases fat mass and obesity-associated protein (FTO) elevated. Meanwhile, the m6A binding proteins, YT521-B homology (YTH) domain-containing 1 (YTHDC1), YTHDC2, insulin-like growth factor 2 mRNA binding protein 1 (IGF2BP1), heterogeneous nuclear ribonucleoprotein C (HNRNPC), and HNRNPA2B1 were decreased, while eukaryotic translation initiation factor 3 subunit H (EIF3H) was increased significantly. All these changes of m6A regulators had significant differences between healthy control and NAFLD, but no differences between the NAFL and NASH group. The expression level of RBM15, HNRNPC, and HNRNPA2B1 were related to body fat index. RBM15, YTHDC2, HNRNPC, HNRNPA2B1, and EIF3H were related to steatosis. Also, KIAA1429 and YTH domain family 1 (YTHDF1) were related to lobular inflammation. Taken together, m6A regulators were involved in the occurrence of NAFLD. More importantly, abnormal MYC was determined as a key link to m6A regulation of NAFLD. The higher MYC mRNA level was accompanied by higher HDL cholesterol and unsaturated fatty acid proportions, as well as lower fat mass, glucose, and transaminase. Taken together, dysregulation of m6A methylation caused steatosis and fibrosis, affecting the occurrence of NAFLD, and MYC might be its potential target.

show abstract

Section: Discussionmentioning

confidence: 99%

New roles of N6-methyladenosine methylation system regulating the occurrence of non-alcoholic fatty liver disease with N6-methyladenosine-modified MYC

Cheng

Zhang

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“… 57 lncRNA XIST regulated by m6A writer METTL14 contributed to proliferation and metastasis of colorectal cancer. 58 METTL3 as a m6A writer could regulated lncRNA ABHD11‐AS1 in lung cancer, 24 lncRNA FOXD2‐AS1 in cervical cancer, 25 lncRNA SNHG7 in prostate cancer, 59 etc. Nevertheless, no study revealed the regulatory effect of METTL3 on lncRNA in OC, although the oncogenic function of METTL3 in OC has been confirmed.…”

Section: Discussionmentioning

confidence: 99%

METTL3‐mediated m6A modification of lnc RNA RHPN1‐AS1 enhances cisplatin resistance in ovarian cancer by activating PI3K/AKT pathway

Cui

2022

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background Cisplatin resistance is a big challenge for ovarian cancer (OC) therapy. The abnormal expression of long noncoding RNAs (lncRNAs) regulated by N6‐methyladenosine (m6A) modification has been confirmed to play the crucial roles in OC. The aim of this study is to explore the regulatory mechanism of lncRNA RHPN1‐AS1 on OC with cisplatin resistance. Methods The real‐time reverse transcription‐polymerase chain reaction was carried out to confirm the expression of RHPN1‐AS1 and methyltransferase‐like 3 (METTL3) in OC. The effects of RHPN1‐AS1 on cisplatin‐resistant OC cells were identified by cell functional experiments and animal experiment. Western blotting was performed to detect the effect of RHPN1‐AS1 on PI3K/AKT pathway. Moreover, methylated RNA immunoprecipitation and RNA stability assays confirmed the interaction between RHPN1‐AS1 and METTL3. Results RHPN1‐AS1 and METTL3 were confirmed to be overexpressed in OC. After transfecting RHPN1‐AS1 overexpression or RHPN1‐AS1 knockdown vectors into cisplatin‐resistant OC cells, it was found that upregulating RHPN1‐AS1 contributed to cell viability, migration, invasion, and tumor growth in vivo. In addition, RHPN1‐AS1 could enhance the protein levels of PI3K and phosphorylated AKT in cisplatin‐resistant OC cells, and METTL3 could enhance the stability of RHPN1‐AS1 by the m6A modification. Conclusion Overall, this study revealed that METTL3‐mediated m6A modification of RHPN1‐AS1 accelerates cisplatin resistance in OC by activating PI3K/AKT pathway.

show abstract

“…Liu et al. [ 254 ] found that METTL3‐stabilized lncRNA SNHG7 accelerated glycolysis in PRAD via the SRSF1/c‐Myc axis (Fig. 8H ).…”

Section: The M 6 a Modification And Cancer Metabolismmentioning

confidence: 97%

“…(H) METTL3 targets lncRNA SNHG7 to increase its mRNA level. SNHG7 regulated c‐Myc via interacting with SRSF1 to promote glycolysis via SRSF1/c‐Myc axis in PRAD cells [ 254 ]. (I) YTHDC1 promotes the maturation of miR‐30d to increase its expression, which further regulates the expression of RUNX1, SLC2A1 and HK1 and therefore attenuates the Warburg effect in pancreatic ductal adenocarcinoma cells [ 62 ].…”

Section: The M 6 a Modification And Cancer Metabolismmentioning

confidence: 99%

RNA m⁶Amethylation in cancer

et al. 2022

View full text Add to dashboard Cite

N 6 -methyladenosine (m 6 A) is one of the most abundant internal modifications in eukaryotic messenger RNAs (mRNAs) and non-coding RNAs (ncRNAs). It is a reversible and dynamic RNA modification that has been observed in both internal coding segments and untranslated regions. Studies indicate that m 6 A modifications play important roles in translation, RNA splicing, export, degradation and ncRNA processing control. In this review, we focus on the profiles and biological functions of RNA m 6 A methylation on both mRNAs and ncRNAs. The dynamic modification of m 6 A and its potential roles in cancer development are discussed. Moreover, we discuss the possibility of m 6 A modifications serving as potential biomarkers for cancer diagnosis and targets for therapy.RNAs including messenger RNA (mRNA) and noncoding RNA (ncRNA). The N6 position of adenosine can be reversibly methylated and unmethylated by 'm 6 A writer' and 'm 6 A eraser' proteins, respectively, and m 6 A RNA can be recognized and bound by 'm 6 A reader' proteins [2] (Fig. 1, Table 1, Box 1).

show abstract

METTL3-stabilized lncRNA SNHG7 accelerates glycolysis in prostate cancer via SRSF1/c-Myc axis

Cited by 40 publications

References 31 publications

New roles of N6-methyladenosine methylation system regulating the occurrence of non-alcoholic fatty liver disease with N6-methyladenosine-modified MYC

New roles of N6-methyladenosine methylation system regulating the occurrence of non-alcoholic fatty liver disease with N6-methyladenosine-modified MYC

METTL3‐mediated m6A modification of lnc RNA RHPN1‐AS1 enhances cisplatin resistance in ovarian cancer by activating PI3K/AKT pathway

RNA m⁶Amethylation in cancer

Contact Info

Product

Resources

About

METTL3-stabilized lncRNA SNHG7 accelerates glycolysis in prostate cancer via SRSF1/c-Myc axis

Cited by 40 publications

References 31 publications

New roles of N6-methyladenosine methylation system regulating the occurrence of non-alcoholic fatty liver disease with N6-methyladenosine-modified MYC

New roles of N6-methyladenosine methylation system regulating the occurrence of non-alcoholic fatty liver disease with N6-methyladenosine-modified MYC

METTL3‐mediated m6A modification of lnc RNA RHPN1‐AS1 enhances cisplatin resistance in ovarian cancer by activating PI3K/AKT pathway

RNA m6Amethylation in cancer

Contact Info

Product

Resources

About

RNA m⁶Amethylation in cancer